554 related articles for article (PubMed ID: 33288348)
1. COVID-19 and treating incarcerated populations for opioid use disorder.
Donelan CJ; Hayes E; Potee RA; Schwartz L; Evans EA
J Subst Abuse Treat; 2021 May; 124():108216. PubMed ID: 33288348
[TBL] [Abstract][Full Text] [Related]
2. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
[TBL] [Abstract][Full Text] [Related]
3. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
Brezel ER; Powell T; Fox AD
Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
[TBL] [Abstract][Full Text] [Related]
4. "And Then COVID Hits": A Qualitative Study of How Jails Adapted Services to Treat Opioid Use Disorder During COVID-19.
Harrington C; Bailey A; Delorme E; Hano S; Evans EA
Subst Use Misuse; 2023; 58(2):266-274. PubMed ID: 36510800
[No Abstract] [Full Text] [Related]
5. Correlates and Patterns in Use of Medications to Treat Opioid Use Disorder in Jail.
Bailey A; Senthilkumar R; Evans EA
J Addict Med; 2023 Sep-Oct 01; 17(5):568-573. PubMed ID: 37788611
[TBL] [Abstract][Full Text] [Related]
6. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
[TBL] [Abstract][Full Text] [Related]
7. Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder.
Evans EA; Wilson D; Friedmann PD
Drug Alcohol Depend; 2022 Feb; 231():109254. PubMed ID: 35063323
[TBL] [Abstract][Full Text] [Related]
8. United States county jail treatment and care of pregnant incarcerated persons with opioid use disorder.
Benck KN; Seide K; Jones AK; Omori M; Rubinstein LB; Beckwith C; Nowotny KM
Drug Alcohol Depend; 2023 Jun; 247():109863. PubMed ID: 37071946
[TBL] [Abstract][Full Text] [Related]
9. Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts.
Evans EA; Pivovarova E; Senthilkumar R; Rottapel RE; Stopka TJ; Santelices C; Ferguson WJ; Friedmann PD
Int J Drug Policy; 2023 Dec; 122():104252. PubMed ID: 37980776
[TBL] [Abstract][Full Text] [Related]
10. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
11. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
12. Diffusion of medications for opioid use disorder treatment in jail settings: a convergent mixed methods study of jail staff perspectives.
Michener PS; Evans EA; Ferguson WJ; Friedmann PD
Addict Sci Clin Pract; 2024 Feb; 19(1):10. PubMed ID: 38347634
[TBL] [Abstract][Full Text] [Related]
13. Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration.
Cherian T; Lim S; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; Rosner Z; MacDonald R; Lee JD
Drug Alcohol Depend; 2024 Jun; 259():111274. PubMed ID: 38643529
[TBL] [Abstract][Full Text] [Related]
14. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
[TBL] [Abstract][Full Text] [Related]
15. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
[TBL] [Abstract][Full Text] [Related]
16. Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail.
Evans EA; Pivovarova E; Stopka TJ; Santelices C; Ferguson WJ; Friedmann PD
J Subst Abuse Treat; 2022 Jul; 138():108746. PubMed ID: 35249789
[TBL] [Abstract][Full Text] [Related]
17. Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
Andraka-Christou B; Atkins D
Am J Drug Alcohol Abuse; 2020 Nov; 46(6):749-760. PubMed ID: 32969757
[TBL] [Abstract][Full Text] [Related]
18. Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder.
Banta-Green CJ; Williams JR; Sears JM; Floyd AS; Tsui JI; Hoeft TJ
Drug Alcohol Depend; 2020 Feb; 207():107799. PubMed ID: 31865058
[TBL] [Abstract][Full Text] [Related]
19. Emergency department utilization by individuals with opioid use disorder who were recently incarcerated.
Will J; Abare M; Olson M; Chyorny A; Wilhelm-Leen E
J Subst Abuse Treat; 2022 Oct; 141():108838. PubMed ID: 35868162
[TBL] [Abstract][Full Text] [Related]
20. Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.
Treitler PC; Enich M; Reeves D; Crystal S
Subst Abus; 2022; 43(1):964-971. PubMed ID: 35420973
[No Abstract] [Full Text] [Related]
[Next] [New Search]
